Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

NCT05616013 on ClinicalTrials.gov · last registry update 2026-07-08

An unusually large phase 2: 507 participants, more than double the 110 typical for the stage. The sponsor logged completion for 16 May 2024. Primary outcome, as filed: Change From Baseline in Body Weight at Week 48. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 507
Started: 2022-11-16
Primary completion: 2024-05-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Body Weight at Week 48

Conditions studied

Obesity · Obese · Overweight or Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.